

1 **Title: Critical role of PP2A-B56 family protein degradation in HIV-1 Vif mediated G2 cell cycle arrest**

2

3 **Author names:**

4 Kayoko Nagata, Keisuke Shindo, Yusuke Matsui, Kotaro Shirakawa and Akifumi Takaori-Kondo

5

6 **Affiliation:**

7 Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University

8

9 **Correspondence**

10 Keisuke Shindo, Department of Hematology and Oncology, Graduate School of Medicine, Kyoto

11 University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507, Japan.

12 E-mail: shind009@kuhp.kyoto-u.ac.jp

13

14 **Abstract**

15 HIV-1 Vif forms an E3 ubiquitin ligase complex with host proteins to counteract host restrictive APOBEC3,
16 and is also known to accumulate infected cells at the G2 phase to promote viral replication. However, the
17 underlying mechanism of how Vif induces G2 arrest is not fully understood, and more specifically, direct
18 target molecules of G2 arrest have not been identified. Here we show that degradation of B56 family
19 proteins (PP2A-B56), one of the regulatory subunits of protein phosphatase 2A, is critical for the Vif-
20 induced G2 arrest. NL4-3 Vif caused degradation of PP2A-B56, and complementation of PP2A-B56
21 overcome the Vif-induced arrest. Supportively, knockdown of PPP2R5D, one of PP2A-B56, by siRNA
22 itself induced cell cycle arrest of non-infected cells. We also identified Vif residues I31 and R or K33 are
23 determinants for inducing G2 arrest, and Vif variants that did not cause G2 arrest did not induce PPP2R5D
24 degradation, although it maintain the ability to induce APOBEC3G degradation, showing strong correlation
25 between Vif-induced arrest and PP2A-B56 degradation. In a sequence database of HIV-1 isolates, Vif strains
26 harboring residues that presumably induce cell cycle arrest are approximately 43%, suggesting Vif-induced
27 G2 arrest contributes to HIV-1 infection *in vivo* and spread. Our data help understand the mechanism of
28 Vif-mediated arrest, and gain insights into general cell cycle regulation.

29

30 Keywords: Virion infectivity factor, PP2A, HIV-1, cell cycle arrest, ubiquitination

31

32 **Introduction**

33

34 Viruses modify intracellular environment of infected cells in several ways, and cell cycle alteration is one
35 such way for several viruses. HIV-1 infection is also known to cause accumulation of infected cells at G2
36 phase. The transcription of the HIV-1 long terminal repeat is very high during the G2 phase in HIV-1
37 infected cells, resulting in efficient viral replication [1], therefore intracellular environment during the G2
38 phase of HIV-1 infected cells is thought to be optimized for viral replication. This cell cycle arrest by HIV-
39 1 has long been attributed to the function of an accessory protein Vpr, and several groups reported the
40 molecular mechanism of Vpr-induced cell cycle arrest. However, since HIV-1 with loss-of-function mutants
41 of Vpr also caused G2 arrest, the involvement of another viral protein was suggested. The mutant of HIV-
42 1 that both vpr and vif genes were deleted is incapable of inducing G2 arrest [2], and the expression of Vif
43 alone is sufficient for G2 arrest [3], indicating the involvement of Vif in G2 arrest. HIV-1 Vif forms a complex
44 with the E3 ubiquitin ligase complex comprising cellular proteins, cullin-5, elongin B, elongin C, RING-box
45 protein 2 and a transcriptional co-activator, CBF β . The resulting Vif-E3 ligase complex targets a host antiviral
46 defense protein APOBEC3, and induces its degradation through the ubiquitin-dependent proteasome pathway,
47 leading to the enhancement of HIV-1 replication [4,5]. The same Vif-E3 ligase complex is required for G2 arrest
48 [6]. Interestingly, The variants of Vif such as NL4-3 Vif causes cell cycle arrest, but HXB2 Vif does not [7,8].
49 However, a direct target molecule for the Vif-mediated arrest has not been identified.

50 Recently, a proteome analysis of the HIV-1 infected cells has identified B56 family proteins of
51 PP2A B subunit, PPP2R5A-E, as novel substrates of the Vif-E3 ligase complex [9]. PP2A is a hetero-
52 trimeric holoenzyme comprising three subunits; B (regulatory) subunit defines the substrate selectivity,
53 while A (scaffold) and C (catalytic) subunits form the core enzyme. B subunit proteins are classified into
54 four subfamilies according to their amino acid sequence similarity: PR55, B56, PR72, and Striatin [10].
55 Although the functions of PP2A-B56 are largely unknown, based on the evidence that another family of
56 PP2A B subunit, PP2A-PR55, play roles as a negative regulator of cell cycle, we hypothesized that the
57 degradation of the PP2A-B56 may be one of the key events in the Vif-mediated G2 arrest. Here, we report
58 PP2A-B56 are the direct target for the Vif-mediated arrest. Moreover, we demonstrate that NL4-3 Vif-
59 induced arrest is suppressed by the overexpression of each of the five PP2A-B56 members, while the G2
60 cell cycle arrest of the non-infected cells are induced by the siRNA inhibition of PPP2R5D in 293T cells.
61 Additionally, we confirm that I31 and R33 residues of NL4-3 Vif are involved in the binding of PPP2R5D,
62 and by substitution of these residues, we demonstrate the strong correlation between PPP2R5D degradation
63 and G2 arrest. Our data establish the critical role of PP2A-B56 degradation in the HIV-1 Vif-mediated arrest,
64 and provide additional information on general regulation of the cell cycle.

65

66 **Material and methods**

67

68 *Cell culture*

69 293T cells were cultured in Dulbecco's modified Eagle's medium (Nacalai Tesque, Japan) supplemented
70 with 10% fetal bovine serum (FBS, Gibco) and penicillin, streptomycin, and glutamine (PSG, Gibco).

71 CEM-SS cells were cultured in RPMI1640 medium (Nacalai) supplemented with 10% FBS and PSG.

72

73 *Plasmid construction*

74 Firstly, oligonucleotides 5'-GATCAAGATCTATCGATGCGGCCGCAGGATCCG-3' and 5'-
75 TCGACGGATCCTGCGGCCGCATCGATAGATCTT-3' (Fasmac) were annealed and inserted into pDON-
76 AI (Takara) at *Bam*HI/*Sal*I sites to introduce additional restriction sites, *Bgl*III, *Cla*I, *Not*I, *Bam*HI, and *Sal*I,
77 and resulting plasmid was named pDON-AI-MCS2. Secondly, the *IRES-GFP* gene was cleaved out from
78 the pCSII-CMV-MCS-IRES-hrGFP using *Not*I and *Hpa*I, and inserted into pDON-AI-MCS2 at *Not*I/*Hpa*I
79 sites. The generated plasmid was named pDON-AI-IRES-GFP. Thirdly, each of the coding sequences for
80 NL4-3 Vif and its various mutants was amplified by polymerase chain reaction (PCR) and inserted into the
81 pDON-AI-IRES-GFP, individually. Expression plasmids for PPP2R5A, PPP2R5B, PPP2R5C-myc,
82 PPP2R5D-myc, and PPP2R5E were produced by amplifying their coding sequences by PCR and inserted
83 into pcDNA3 (Invitrogen), individually. The Flag-tagged ubiquitin expression plasmid was previously
84 described [7].

85

86 *Transfection and virus infection*

87 For cell cycle analysis, 293T cells were transfected by using Calphos mammalian transfection kit (Clontech)
88 according to the manufacturer's instructions. For immunoprecipitation, 293T cells were transfected by
89 using X-tremegene HP DNA transfection reagent (Roche) according to the manufacturer's instructions. For
90 retrovirus preparation, 293T cells were transfected using polyethyleneimine (PEI) at a PEI: DNA ratio of
91 2.25: 1 (w: w). Forty-eight hours after transfection, virus-containing supernatants were harvested through
92 the 0.45 μm pore-sized PVDF filter, and subsequently concentrated by ultracentrifugation. CEM-SS cells
93 were then inoculated with the concentrated virus for 72 h.

94

95 *Immunoblotting*

96 For immunoblotting, we used a general chemiluminescence protocol with PVDF membrane (Millipore).
97 Following primary antibodies were used: anti-Vif, anti-PPP2R5A, anti-PPP2R5B, anti-PPP2R5C, anti-
98 PPP2R5D, and anti-PPP2R5E (Santa Cruz); anti- β -actin, anti-c-Myc, and anti-Flag (Sigma-Aldrich); anti-
99 A3G (NIH AIDS Reagent Program).

100

101 *Cell cycle analysis*

102 To detect cell cycle arrest, DNA contents of transfected 293T cells and infected CEM-SS cells were
103 examined using flow cytometry. Either 48 h after transfection or 72 h after infection, cells were harvested,

104 washed with PBS, and then fixed in ice-cold 70% ethanol at 4°C. Cells were then washed with 2% FBS/PBS,
105 stained with propidium iodide (Nacalai) at 10 µg/ml containing 200 µg/ml RNase A (QIAGEN) and 2%
106 FBS/PBS at 37°C, and examined on a FACSCalibur flow cytometer (Becton Dickinson). Data were
107 analyzed with Flowjo software.

108

109 *Co-immunoprecipitation*

110 Transfected 293T cells were treated with MG132 (Calbiochem) at 2.5 µM for 16 h, and lysed with co-IP
111 buffer (50 mM Tris pH8.0, 250 mM NaCl, 5 mM EDTA, and 0.3% CHAPS) supplemented with protease
112 inhibitor cocktail (Roche) and 50 µM MG132. Lysates were immunoprecipitated with anti-myc antibody
113 for 3 h at 4°C, and then mixed with protein A or G sepharose beads (GE Healthcare) for 2 h. Beads were
114 washed with co-IP buffer, and bound proteins were eluted and analyzed by immunoblotting.

115

116 **Results**

117

118 *The formation of the Vif-E3 ligase complex is required for the Vif-induced cell cycle arrest*

119

120 Previous studies on Vif-mediated arrest utilized fluorescent protein to extract Vif-expressing cells by co-
121 transfection [8] or fusion protein [7]. These approaches were basically successful, however, substitutional

122 analyses of Vif amino acid residues sometimes caused inconsistent results, because of the low efficiency of
123 arrest induction. To analyze the Vif-induced arrest more sensitively, we successfully took advantage of
124 IRES-containing expression vector that simultaneously expresses Vif and EGFP proteins. By using this
125 vector in 293T cells, the ratio of Vif-expressing cells at G2/M phase over those at G1 phase increased to
126 around two, whereas that of empty-vector-transfected cells remained around 0.7 (Supplementary Figures
127 1C and 1D). We first aimed to confirm the previous report that the formation of the Vif-E3 ligase complex
128 is required for the Vif-mediated arrest [6]. We generated three kinds of Vif amino acid substitutions C133S
129 [4], ¹⁴⁴SLQ¹⁴⁶/AAA [11,12], and E88A/W89A [13], into the Vif-IRES-EGFP vector (Supplementary Figure
130 1A). All these Vif mutants do not form functional E3 ligase complex, therefore are incapable of degrading
131 APOBEC3G (Supplementary Figure 1B). We then performed cell cycle analysis on 293T cells using these
132 vectors. The cell number in the G2/M phase was remarkably increased by expressing Vif wild-type, but not
133 by any of the Vif mutants tested (Supplementary Figures 1C and 1D), indicating that the formation of the
134 Vif-E3 ligase complex is required for G2 arrest.

135

136 *PP2A-B56 are substrates for the Vif-E3 ligase complex and affect cell cycle progression*

137

138 A proteomic approach has recently identified that the members of PP2A-B56, including PPP2R5A, B, C,
139 D, and E, are substrates of the Vif-E3 ligase complex [9]. We next examined whether Vif-induced

140 degradation of PP2A-B56 is related to the Vif-induced arrest. To confirm that PP2A-B56 are degraded by
141 Vif, 293T cells were transfected with the expression vector for NL4-3 Vif, HXB2 Vif, SLQ mutant, or
142 empty vector, and then PP2A-B56 levels were analyzed by immunoblotting. Of note, NL4-3 Vif is capable
143 of inducing G2 arrest, but HXB2 Vif is not [7]. PPP2R5A level in the cells expressing either NL4-3 Vif or
144 HXB2 Vif was lower than that in the cells transfected with the empty vector or SLQ mutant, while the levels
145 of PPP2R5B, C, and E were not clearly determined because of low endogenous expression levels (Figure
146 1A). Interestingly, PPP2R5D level in the cells expressing NL4-3 Vif was lower than that in the cells
147 expressing either HXB2 Vif or SLQ mutant, or that in the cells with the empty vector (Figure 1A). We next
148 examined whether exogenously expressed PP2A-B56 are degraded by Vif. Each of PP2A-B56 expression
149 vector is co-transfected with the expression vector for NL4-3 Vif, or empty vector, then PP2A-B56 levels
150 were analyzed. The levels of PPP2R5A, B, C, D, and E in NL4-3 Vif expressing cells were lower than those
151 in empty vector transfected cells (Figure 2B). These results indicate that all of PP2A-B56 are substrates of
152 the NL4-3 Vif-E3 ligase, consistent with the previous report. Because the downregulation of endogenous
153 PPP2R5D was most clearly observed in 293T cells, we used PPP2R5D as a prototype to confirm the
154 relationship between PP2A-B56 degradation and the Vif-mediated arrest in 293T cells.

155 We further confirmed that PPP2R5D is a substrate of the Vif-E3 ubiquitin ligase complex.
156 Treatment of MG132, a proteasome inhibitor, restored the level of PPP2R5D downregulated by Vif
157 expression (Supplementary Figure 2A). Interaction between Vif and PPP2R5D was confirmed by co-

158 immunoprecipitation experiments (Supplementary Figure 2B). Additionally, poly-ubiquitination of
159 PPP2R5D in the Vif expressing cells was higher than that in empty vector transfected cells (Supplementary
160 Figure 2C). Altogether, these results support that PPP2R5D is a substrate of Vif-E3 ligase complex.

161 We next performed complementation experiments. If the degradation of PPP2R5D is required for
162 the Vif-mediated arrest, complementation of PPP2R5D by co-transfection would counteract G2 arrest. 293T
163 cells were co-transfected with the expression vectors for Vif and one of PP2A-B56 and cell cycles were
164 analyzed. Consistent with our expectation, co-expression of Vif and PPP2R5D did not induce G2 arrest.
165 Surprisingly, co-expression of Vif and PP2R5A, B, C, or E also did not induce G2 arrest (Figures 1C and
166 1D), suggesting that all of PP2A-B56 family members individually work in counteracting the Vif-induced
167 arrest.

168 Additionally, to investigate whether down-regulation of PPP2R5D is sufficient to induce cell
169 cycle arrest, we performed knockdown experiments of PPP2R5D. 293T cells were transfected with one of
170 two different siRNAs targeting PPP2R5D [siPPP2R5D (878) and siPPP2R5D (939)], or non-silencing
171 control RNA. The efficiency of the knockdown was analyzed by immunoblotting (Figure 1E). We then
172 analyzed these cells for cell cycle, and found accumulation of cells at G2/M phase (Figures 1F and 1G),
173 suggesting that targeting of PPP2R5D alone for degradation is sufficient for cell cycle arrest in 293T cells.

174

175 *I31 and R33 residues of NL4-3 Vif are critical for the PPP2R5D degradation*

176

177 To further examine the correlation between Vif-induced arrest and PPP2R5D degradation, we next aimed
178 to identify Vif residues that recognize PPP2R5D. A couple of previous studies of amino acid substitution
179 between NL4-3 Vif and HXB2 Vif have identified six residues, I31, R33, K36, Y47, H48 and K50, as Vif
180 determinants for G2 arrest [7,8] (Figure 2A). We expressed six NL4-3 Vif mutants, I31V/R33G/K36R, I31V,
181 R33G, K36R, T47P/K50R, and H48N, individually, in 293T cells and analyzed their effects on cell cycle.
182 Consistent with the previous report, I31V/R33G/K36R, I31V, or R33G did not induce G2 arrest, however,
183 K36R, T47P/K50R, and N48H appeared to induce G2 arrest to some extent (Figures 2B and 2C). These
184 results indicate that I31 and R33 residues of NL4-3 Vif are critical for the Vif-induced arrest. We then
185 examined protein levels of PPP2R5D in the cells expressing each of the Vif mutants by immunoblotting.
186 PPP2R5D decreased in the cells expressing Vif wild-type, K36R, T47P/K50R, or N48H, but not in the cells
187 expressing I31V/R33G/K36R, I31V or R33G (Figure 2D). To exclude the possibility that these mutants do
188 not form the functional Vif-E3 ligase complex, APOBEC3G degradation was examined. All of the Vif
189 mutants definitely induced APOBEC3G degradation (Figure 2E), indicating that these Vif mutants work as
190 an E3 ubiquitin ligase.

191 Considering that I31V and R33G induced APOBEC3G degradation, but not PPP2R5D
192 degradation, Vif I31 and R33 might interact with PPP2R5D. To examine this possibility, we performed co-
193 immunoprecipitation experiments with Vif I31V/R33G. The amount of PPP2R5D co-precipitated with

194 myc-tagged Vif I31V/R33G appeared to be lower than that co-precipitated with myc-tagged Vif wild-type
195 (Figure 2F), suggesting that the residues I31 and R33 are involved in PPP2R5D binding. Altogether, these
196 results indicate that the Vif-mediated arrest and PPP2R5D degradation strongly correlates, and that the
197 residues I31 and R33 of NL4-3 Vif play the central role in the PPP2R5D recognition.

198

199 *Vif variants harboring K33 is capable of inducing the cell cycle arrest*

200

201 So far, we examined Vif residues based on amino acid sequences of NL4-3 Vif and HXB2 Vif. According
202 to the HIV-1 sequence database by Los Alamos National Laboratory (LANL,
203 <http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html>), isoleucine (NL4-3) and valine (HXB2) are
204 two major residues for Vif position 31, but lysin, not arginine (NL4-3) or glycine (HXB2), is the most
205 frequent residue for position 33 (Figure 3A). To examine whether Vif variants harboring K33 induce G2
206 arrest, we expressed NL4-3 Vif R33K in 293T cells, and analyzed its effect on cell cycle. Interestingly, Vif
207 R33K induced G2 arrest of transfected cells comparably to NL4-3 Vif wild-type (Figure 3B). PPP2R5D
208 degradation by Vif R33K was confirmed by immunoblotting (Figure 3C), consistent with the idea that
209 PPP2R5D degradation is relevant to the Vif-mediated arrest. APOBEC3G was also downregulated by Vif
210 R33K (Figure 3D). To speculate contributions of Vif residues other than I31 and R/K33 to Vif-mediated
211 arrest, we generated expression vectors for HXB2 Vif V31I/G33R and V31I/G33K mutants. Both of these

212 mutants strongly induced G2 arrest (Figure 3E), and degradation of PPP2R5D (Figure 3F) and APOBEC3G
213 (Figure 3G), suggesting little contributions of other residues to PPP2R5D recognition. Taken together, Vif
214 strains harboring I31 and R/K33, which consist of the majority of isolated strains, are likely to induce G2
215 arrest.

216

217 *PP2A-B56 degradation is relevant to HIV-1 Vif-induced arrest in T cells*

218

219 To confirm our findings in more physiological condition, we used a T cell line in which HIV-1 can replicate. We
220 examined endogenous levels of PP2A-B56 and their degradation by Vif in CEM-SS cells. CEM-SS cells were
221 retrovirally transduced with NL4-3 Vif, HXB2 Vif, or empty vector, and then PP2A-B56 levels were analyzed
222 by immunoblotting (Figure 4A). PPP2R5A was degraded by either NL4-3 Vif or HXB2 Vif, while PPP2R5D
223 were degraded only by NL4-3 Vif, similarly to the results obtained with 293T cells. The endogenous PPP2R5B
224 and C in CEM-SS cells were not detected by immunoblotting. Apart from the results with 293T cells, endogenous
225 PPP2R5E was clearly detected in CEM-SS cells, and degraded by NL4-3 Vif, but not by HXB2 Vif. We next
226 examined whether overexpression of PP2A-B56 counteracts to Vif-mediated arrest. CEM-SS cells were
227 transduced with NL4-3 Vif and PPP2R5C, D, E, or empty vector, and cell cycle were analyzed (Figure 4B).
228 Transduction of NL4-3 Vif accumulated the cells at G2/M phase, and co-transduction of PPP2R5D or E with
229 NL4-3 Vif significantly decreased cells at G2/M phase, compared to Vif-transduced cells. Co-transduction of

230 PPP2R5C with NL4-3 Vif into CEM-SS cells appeared to slightly decrease cells at G2/M phase, compared to
231 Vif-transduced cells, because of weak expression of PPP2R5C (Figure 4C). All of these results from CEM-SS
232 cells are very similar to those in 293T cells (Figure 1). We further examined the potency of Vif mutants for cell
233 cycle arrest induction and PPP2R5D degradation in CEM-SS cells. NL4-3 Vif R33K, N48H, and T47P/K50R
234 induced G2 arrest in CEM-SS cells comparably to NL4-3 Vif wild-type, but I31V/R33G did not (Figure 4D).
235 PPP2R5D protein levels were simultaneously analyzed by immunoblotting, and down-regulated by NL4-3 Vif
236 wild-type, R33K, N48H, and T47P/K50R, but not by I31V/R33G (Figure 4E). All of the data obtained in CEM-
237 SS cells were similar to the result with 293T cells (Figures 2 and 3). Thus, our finding that PP2A-B56 degradation
238 by Vif is relevant to Vif-mediated arrest is likely true in T cells.

239

240 **Discussion**

241

242 We here demonstrate that PP2A-B56 family proteins are the direct targets of Vif-mediated G2 arrest, and
243 that PPP2R5D is most likely to be relevant to G2 arrest in 293T cells. PP2A has been reported to play
244 important roles in the regulation of cell cycle. Basically G2/M transition is regulated by the Cdc25/14-3-3
245 interaction; Dephosphorylation at Ser-218 of Cdc25 triggers its dissociation from 14-3-3 leading to the
246 activation of Cdc25, resulting in G2/M transition. Phosphatases such as PP-1 and PP2A work as a positive
247 regulator in this dephosphorylation. On the other hands, PPP2R5D is shown to play a different role in this

248 step; It dephosphorylates active phosphorylation at Thr-130 of Cdc25, working as a negative regulator[14].

249 Thus, it is quite complicated to evaluate the precise role of PP2A-B56 in the cell cycle regulation.

250 Recently, Salamango *et al.* reported that combinatory suppression of two of PPP2R5A, C, or D
251 causes cell cycle arrest in 293T cells, which are the target of Vif-induced degradation [15]. Their finding is
252 partially different from ours that suppression of PPP2R5D alone is sufficient for G2 arrest. Since we showed
253 that each PP2A-B56 is expressed at different levels depending on cell types, this discrepancy might be
254 attributable to different expression profiles of PP2A-B56 in different cell types. Moreover, we show that
255 complementation of each of the PP2A-B56 overcame the Vif-induced G2 arrest, proving direct relation
256 between Vif-induced arrest and PP2A-B56 degradation.

257 In this study, we clearly demonstrated that NL4-3 Vif I31 and R33 residues are critical for the
258 Vif-mediated arrest and PPP2R5D degradation, but either K36, T47, N48 or K50 is not, supporting the
259 correlation between PPP2R5D degradation and the Vif-mediated arrest. We further elucidated that a major
260 variant K33 is capable of inducing G2 arrest. According to the HIV-1 sequence database by LANL,
261 conservation of both I31 and R/K33 residues of Vif was about 43% (1919/4465). In contrast, according to
262 the reports analyzing the gene sequence of Vif in HIV-1 infected patients, the Vif harboring both I31 and
263 R/K33 was found to be 72% (76/105) in North India [16], 23% (6/26) in South Africa [17], and 48% (37/77)
264 in Mexico [18]. Thus, the frequency of Vif harboring I31 and R/K33 in HIV-1 infected patients varies among
265 regions, but Vif-mediated arrest would happen in the majority of patients with HIV-1 infection, and could

266 be advantageous to HIV-1 infection *in vivo* and spread.

267 We demonstrate that PP2A-B56 are substrate of the majority of HIV-1 Vif strains, and the
268 degradation of PPP2R5D is closely related to Vif-mediated arrest. Our data suggest that PP2A-B56 might
269 play roles in the regulation of the cell cycle through phosphorylation-based signal transduction. Further
270 studies on the Vif-mediated arrest will contribute to elucidate profound regulatory system of the cell
271 cycle.

272

273 **Acknowledgments**

274

275 We thank the laboratory members for helpful discussion. We also thank Dr. Takashi Nagata in Institute of
276 Advanced Energy, Kyoto University for critical reading. Anti-human APOBEC3G C-terminal serum was
277 obtained from Dr. Jaisri Lingappa through the NIH AIDS Reagent Program, Division of AIDS, NIAID,
278 NIH. This work was partly supported by grants-in-aid for scientific research from Japan Society for the
279 Promotion of Science (KAKENHI #JP 16K08807 to Shindo).

280

281 **Figure Legends**

282

283 **Figure 1. PP2A-B56 are substrates for the NL4-3 Vif-E3 ligase complex and effect on cell cycle progression.**

284 (A) Downregulation of PPP2R5D by NL4-3 Vif overexpression. 293T cells were transfected with
285 expression vector for NL4-3 Vif, HXB2 Vif, SLQ mutant, or empty vector (EV), and analyzed for protein
286 levels of endogenous PPP2R5A-E by immunoblotting. Asterisk indicate non-specific signal. (B)
287 Overexpressed PP2A-B56 are downregulated by NL4-3 Vif. 293T cells were co-transfected with expression
288 vectors for each of PP2A-B56 and Vif, and analyzed for PPP2R5A-E levels by immunoblotting. (C)
289 Representative histogram for 293T cells co-transfected with each of PP2A-B56 and Vif. Cells at G1, S, and
290 G2/M phase are colored in *blue*, *yellow*, and *green*, respectively. (D) Bar chart represents the (G2+M)/G1
291 ratios from three independent experiments in (C). Asterisks indicate statistical significances (*: P<0.05, **: P<0.01). (E) Validation of two different siRNA against PPP2R5D. 293T cells were transfected with either
292 non-silencing control RNA, siPPP2R5D (878), or siPPP2R5D (939), and the PPP2R5D protein levels were
293 analyzed by immunoblotting. (F) Representative histogram for 293T cells transfected with each of the two
294 different PPP2R5D siRNAs. (G) Bar chart represents the (G2+M)/G1 ratios from three independent
295 experiments in (F). Asterisks indicate statistical significances (**: P<0.01).

297

298 Figure 2. Identification of Vif residues involved in the recognition of PPP2R5D. (A) Protein sequence
299 alignment of the N-terminal regions of NL4-3 Vif and HXB2 Vif. The residues of HXB2 Vif that are
300 conserved with NL4-3 Vif are indicated by asterisk. (B) Representative histogram for 293T cells transfected
301 with indicated vectors. (C) Bar chart represents the (G2+M)/G1 ratios from three independent experiments

302 in (B). Asterisks indicate statistical significances (*: $P < 0.05$, **: $P < 0.01$). (D) PPP2R5D levels in the cells
303 studied in (B) were analyzed by immunoblotting. (E) Validation of ubiquitin ligase activity of Vif mutants
304 against APOBEC3G. 293T cells were transfected with the expression vector for APOBEC3G and the
305 indicated vector for Vif wild type (WT), mutants, or EV, and the levels of indicated proteins were analyzed
306 by immunoblotting. (F) Impaired co-immunoprecipitation of PPP2R5D with Vif I31V/R33G mutant. 293T
307 cells were transfected with indicated vectors (myc-tagged Vif WT, I31V/R33G, or EV),
308 immunoprecipitated with anti-myc antibody for Vif proteins, and bound proteins were analyzed by
309 immunoblotting.

310

311 Figure 3. A major variant of HIV-1 Vif is capable of inducing cell cycle arrest. (A) An alignment of HIV-1
312 Vif residues 30 to 50. A sequence logo based on the database by LANL and NL4-3 and HXB2 Vif sequence
313 were aligned. (B) Representative histogram for 293T cells transfected with indicated vectors. (C)
314 Immunoblotting analyses of cells in (B). (D) Immunoblotting analyses of APOBEC3G degradation by Vif
315 R33K. (E) Representative histogram for 293T cells transfected with indicated vectors. (F) Immunoblotting
316 analyses of cells in (E). (G) Immunoblotting analyses of APOBEC3G degradation by HXB2 Vif wild-type
317 and mutants.

318

319 Figure 4. Correlation between PP2A-B56 degradation and Vif-induced arrest in T cells. (A) Immunoblotting

320 analysis of endogenous PP2A-B56 protein levels in CEM-SS cells. CEM-SS cells were infected with
321 indicated viruses and analyzed for PP2A-B56 levels by immunoblotting. (B) Complementation of
322 PPP2R5C, D or E impairs Vif-induced arrest in CEM-SS cells. CEM-SS cells were infected with indicated
323 viruses and the cell cycle distribution was analyzed. (C) Immunoblotting analysis of PP2A-B56 protein
324 levels in CEM-SS cells infected with viruses transducing Vif and PP2A-B56. (D) I31 and R/K33 are critical
325 for Vif to induce G2 arrest. CEM-SS cells were infected with indicated viruses and the cell cycle distribution
326 was analyzed. (E) Immunoblotting analyses of the cells in (D).

327

328 **References**

329

- 330 [1] M. Emerman, HIV-1, Vpr and the cell cycle, *Curr Biol* 6 (1996) 1096-1103.
- 331 [2] K. Sakai, J. Dimas, M.J. Lenardo, The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell
332 cytopathicity and cell cycle arrest, *Proc Natl Acad Sci U S A* 103 (2006) 3369-3374.
- 333 [3] J. Wang, J.M. Shackelford, C.R. Casella, et al., The Vif accessory protein alters the cell cycle of human
334 immunodeficiency virus type 1 infected cells, *Virology* 359 (2007) 243-252.
- 335 [4] X. Yu, Y. Yu, B. Liu, et al., Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF
336 complex, *Science* 302 (2003) 1056-1060.
- 337 [5] S.P. Goff, Death by deamination: a novel host restriction system for HIV-1, *Cell* 114 (2003) 281-283.
- 338 [6] J.L. DeHart, A. Bosque, R.S. Harris, V. Planelles, Human immunodeficiency virus type 1 Vif induces cell cycle
339 delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation,
340 *J Virol* 82 (2008) 9265-9272.
- 341 [7] T. Izumi, K. Io, M. Matsui, et al., HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest
342 and positively regulate viral replication, *Proc Natl Acad Sci U S A* 107 (2010) 20798-20803.
- 343 [8] K. Zhao, J. Du, Y. Rui, et al., Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest
344 and A3H inactivation functions in HIV-1 Vif, *Cell Cycle* 14 (2015) 838-847.
- 345 [9] E.J. Greenwood, N.J. Matheson, K. Wals, et al., Temporal proteomic analysis of HIV infection reveals remodelling

346 of the host phosphoproteome by lentiviral Vif variants, *Elife* 5 (2016).

347 [10] Y. Shi, Assembly and structure of protein phosphatase 2A, *Sci China C Life Sci* 52 (2009) 135-146.

348 [11] A. Mehle, J. Goncalves, M. Santa-Marta, M. McPike, D. Gabuzda, Phosphorylation of a novel SOCS-box
349 regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation, *Genes Dev* 18
350 (2004) 2861-2866.

351 [12] Y. Yu, Z. Xiao, E.S. Ehrlich, X. Yu, X.F. Yu, Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3
352 ubiquitin ligase complex through a novel SOCS box and upstream cysteines, *Genes Dev* 18 (2004) 2867-
353 2872.

354 [13] Y. Matsui, K. Shindo, K. Nagata, et al., Defining HIV-1 Vif residues that interact with CBFbeta by site-directed
355 mutagenesis, *Virology* 449 (2014) 82-87.

356 [14] S.S. Margolis, J.A. Perry, C.M. Forester, et al., Role for the PP2A/B56delta phosphatase in regulating 14-3-3
357 release from Cdc25 to control mitosis, *Cell* 127 (2006) 759-773.

358 [15] D.J. Salamango, T. Ikeda, S.A. Moghadasi, et al., HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular
359 PPP2R5 Phospho-regulators, *Cell Rep* 29 (2019) 1057-1065 e1054.

360 [16] L. Ronsard, R. Raja, V. Panwar, et al., Genetic and functional characterization of HIV-1 Vif on APOBEC3G
361 degradation: First report of emergence of B/C recombinants from North India, *Sci Rep* 5 (2015) 15438.

362 [17] K. Reddy, M. Ooms, M. Letko, et al., Functional characterization of Vif proteins from HIV-1 infected patients
363 with different APOBEC3G haplotypes, *AIDS* 30 (2016) 1723-1729.

364 [18] S.E. Guerra-Palomares, P.G. Hernandez-Sanchez, M.A. Esparza-Perez, et al., Molecular Characterization of
365 Mexican HIV-1 Vif Sequences, *AIDS Res Hum Retroviruses* 32 (2016) 290-295.

366

367